An innovative mathematical analysis of routine MRI scans in patients with glioblastoma using DoctorEye
暂无分享,去创建一个
Holger Stenzhorn | Kostas Marias | Vangelis Sakkalis | Georgios C. Manikis | Norbert M. Graf | Georgios S. Stamatakos | Ioannis Karatzanis | Wolfgang Reith | Jonathan Zepp | H. Stenzhorn | W. Reith | V. Sakkalis | G. Stamatakos | N. Graf | K. Marias | G. Manikis | Ioannis Karatzanis | Jonathan Zepp
[1] M. Tsiknakis,et al. The "Oncosimulator": a multilevel, clinically oriented simulation system of tumor growth and organism response to therapeutic schemes. Towards the clinical evaluation of in silico oncology , 2007, 2007 29th Annual International Conference of the IEEE Engineering in Medicine and Biology Society.
[2] Thomas S. Deisboeck,et al. Computational modeling of brain tumors: discrete, continuum or hybrid? , 2008 .
[3] Vangelis Sakkalis,et al. DoctorEye: A multifunctional open platform for fast annotation and visualization of tumors in medical images , 2009, 2009 Annual International Conference of the IEEE Engineering in Medicine and Biology Society.
[4] Nikolaos K. Uzunoglu,et al. A spatiotemporal, patient individualized simulation model of solid tumor response to chemotherapy in vivo: the paradigm of glioblastoma multiforme treated by temozolomide , 2006, IEEE Transactions on Biomedical Engineering.
[5] Albert Lai,et al. Apparent diffusion coefficient histogram analysis stratifies progression-free and overall survival in patients with recurrent GBM treated with bevacizumab: a multi-center study , 2012, Journal of Neuro-Oncology.
[6] A. Brandes,et al. MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] M. Platten,et al. Neuroradiologische Responsekriterien bei malignen Gliomen , 2010, Der Nervenarzt.
[8] M. Rosenthal,et al. Imaging modalities in high-grade gliomas: Pseudoprogression, recurrence, or necrosis? , 2012, Journal of Clinical Neuroscience.
[9] Bart Neyns,et al. Pseudoprogression after radiotherapy with concurrent temozolomide for high-grade glioma: clinical observations and working recommendations. , 2009, Surgical neurology.
[10] Dieta Brandsma,et al. Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. , 2008, The Lancet. Oncology.
[11] R. Luukkonen,et al. Is the signal intensity of cerebrospinal fluid constant? Intensity measurements with high and low field magnetic resonance imagers. , 1993, Magnetic resonance imaging.
[12] Zhihui Wang,et al. Multiscale agent-based cancer modeling , 2009, Journal of mathematical biology.
[13] J. Uhm. Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group , 2010 .
[14] L Leon Chen,et al. An agent-based model identifies MRI regions of probable tumor invasion in a patient with glioblastoma , 2010, Physics in medicine and biology.
[15] T. Cascino,et al. Response criteria for phase II studies of supratentorial malignant glioma. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] Maria I. Argyropoulou,et al. Glioma recurrence versus radiation necrosis: accuracy of current imaging modalities , 2009, Journal of Neuro-Oncology.